The detection of diverse pathogens and chemical compounds in community wastewater facilitates the monitoring of public health trends of emerging diseases and health conditions. During the COVID-19 pandemic, detection of viral RNA in wastewater assisted in monitoring the infection rates in different geographies and this drew attention to the method of wastewater-based epidemiology (WBE). In contrast to individual clinical testing, WBE offers an affordable, population-wide overview of the infection status of a community including asymptomatic carriers and those without access to healthcare facilities. To understand the community status of the infections caused by respiratory syncytial virus, SARS-CoV-2 and influenza virus subtypes in the monsoon season in Vijayawada city in the state of Andhra Pradesh in India, we longitudinally analyzed wastewater samples once a week between July-August 2024 from 7 sewage treatment plants in the city. The data obtained from the multiplexed RT-qPCR was used to calculate the viral loads in the wastewater samples at the city level and the proportion of population shedding the virus was estimated. All three viruses RSV A+B, SARS-CoV-2 and Influenza A+B were detected in the wastewater during our sampling period. Amongst the three viruses, the city had the largest load of SARS-CoV-2 RNA in the wastewater followed by RSV A+B and Influenza A+B. The study demonstrates the potential of utilizing wastewater surveillance system coupled to multiplexed RT-PCR to understand the population level dynamics of co-existence of multiple pathogens during the monsoon season in the urban settings.

The authors have declared no competing interest.

This study was supported by the funding from the Rockefeller Foundation, Grant Number 2021 HTH 018 provided to the Tata Institute for Genetics and Society (TIGS), Centre for Cellular and Molecular Biology (CCMB) and the National Centre for Biological Sciences (NCBS). The study is also supported by the institutional core funding to Tata Institute for Genetics and Society by the Tata Trusts.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present work are contained in the manuscript